Cedazuridine positive in Ames and in vitro chromosome aberration assays; negative in in vivo micronucleus
“Cedazuridine was mutagenic in the Ames assay and genotoxic in the in vitro chromosome aberration assay, but not genotoxic in the in vivo micronucleus assay.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗
Carcinogenicity
Not conducted (advanced cancer indication, ICH S9)
“Per ICH S9, we agree that carcinogenicity studies are not needed to support the approval of ASTX727 for the proposed indication.”
✓ VerifiedFDA multi-discipline review, p. 66Source ↗
Reproductive & developmental
Not conducted (ICH S9); malformation or embryofetal lethality expected
“per ICH S9, reproductive and developmental toxicity studies are not needed for this class of drugs. These drugs are expected to cause malformation or embryofetal lethality.”
✓ VerifiedFDA multi-discipline review, p. 67Source ↗
Safety pharmacology
Cedazuridine: no cardiovascular or respiratory findings in single-dose monkey study up to 200 mg/kg
“There were no cardiovascular or respiratory findings in a single-dose standalone safety pharmacology study in cynomolgus monkeys with oral doses of cedazuridine up to 200 mg/kg.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative